Osimertinib versus comparator first-generation epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in patients with advanced EGFR-mutated non-small cell lung cancer: a Chinese, multicenter, real-world cohort study

被引：3

作者：

Zhang, Dongming ^{[1
]}

Liu, Xiaoyan ^{[1
]}

Shen, Fangfang ^{[2
]}

Zhao, Dahai ^{[3
]}

Shi, Yuequan ^{[1
]}

Zhang, Haoran ^{[1
]}

Liu, Jia ^{[1
]}

Gao, Xiaoxing ^{[1
]}

Chen, Minjiang ^{[1
]}

Zhao, Jing ^{[1
]}

Zhong, Wei ^{[1
]}

Gao, Junzhen ^{[4
]}

He, Min ^{[5
]}

Liu, Yonggang ^{[6
]}

Yang, Xiaoling ^{[7
]}

Qin, Jianwen ^{[8
]}

Tang, Yuling ^{[9
]}

Mu, Xinlin ^{[10
]}

Gu, Yangchun ^{[11
]}

Zhang, Shucai ^{[12
]}

Chen, Xueqin ^{[13
]}

Pang, Li ^{[14
]}

Meng, Qingwei ^{[15
]}

Guo, Ye ^{[16
]}

Zhang, Yuhui ^{[17
]}

Li, Wei ^{[18
]}

Xing, Puyuan ^{[19
]}

Cheng, Yuan ^{[20
]}

Xin, Tao ^{[21
]}

Li, Qingxia ^{[22
]}

Li, Yu ^{[23
]}

Chen, Jun ^{[24
]}

Gao, Feng ^{[25
]}

Jin, Bo ^{[26
]}

Rossi, Antonio ^{[27
]}

Adachi, Hiroyuki ^{[28
]}

Guerrera, Francesco ^{[29
,30
]}

Husain, Hatim ^{[31
]}

Xu, Yan ^{[1
]}

Wang, Mengzhao ^{[1
]}

机构：

[1] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Resp & Crit Care Med, Beijing, Peoples R China

[2] Shanxi Med Univ, Shanxi Prov Canc Hosp, Canc Hosp, Dept Resp Med, Taiyuan, Peoples R China

[3] Anhui Med Univ, Affiliated Hosp 2, Dept Resp & Crit Care Med, Hefei, Peoples R China

[4] Inner Mongolia Med Univ, Dept Resp & Crit Care Med, Affiliated Hosp, Hohhot, Inner Mongolia, Peoples R China

[5] Inner Mongolia Autonomous Reg Peoples Hosp, Dept Oncol, Hohhot, Inner Mongolia, Peoples R China

[6] Baotou Canc Hosp, Dept Thorac Oncol, Baotou, Inner Mongolia, Peoples R China

[7] Shanxi Med Univ, Shanxi Bethune Hosp, Dept Thorac Oncol, Hosp 3, Taiyuan, Peoples R China

[8] Tianjin Chest Hosp, Dept Resp & Crit Med, Tianjin, Peoples R China

[9] First Hosp Changsha, Resp Med Ctr, Changsha, Peoples R China

[10] Peking Univ, Dept Resp & Crit Care Med, Peoples Hosp, Beijing, Peoples R China

[11] Peking Univ, Dept Med Oncol & Radiat Sickness, Hosp 3, Beijing, Peoples R China

[12] Capital Med Univ, Beijing Chest Hosp, Dept Oncol, Beijing, Peoples R China

[13] Zhejiang Univ, Hangzhou Canc Hosp, Sch Med, Dept Thorac Oncol, Hangzhou, Peoples R China

[14] Capital Med Univ, Beijing Shijitan Hosp, Dept Resp & Crit Care, Beijing, Peoples R China

[15] Harbin Med Univ, Canc Hosp, Dept Med Oncol, Harbin, Peoples R China

[16] First Hosp Jilin Univ, Canc Ctr, Changchun, Peoples R China

[17] Capital Med Univ, Beijing Chao Yang Hosp, Dept Resp & Crit Care Med, Beijing, Peoples R China

[18] Bengbu Med Coll, Dept Resp & Crit Care Med, Affiliated Hosp 1, Bengbu, Peoples R China

[19] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Clin Res Ctr Canc, Natl Canc Ctr,Dept Med Oncol, Beijing, Peoples R China

[20] Peking Univ First Hosp, Dept Resp & Crit Care Med, Beijing, Peoples R China

[21] Harbin Med Univ, Affiliated Hosp 2, Dept Oncol, Harbin, Peoples R China

[22] Hebei Gen Hosp, Dept Oncol, Shijiazhuang, Peoples R China

[23] Shandong Univ, Dept Resp Med, Qilu Hosp, Jinan, Peoples R China

[24] Tianjin Med Univ, Tianjin Lung Canc Inst, Dept Lung Canc Surg, Gen Hosp, Tianjin, Peoples R China

[25] Beidahuang Ind Grp, Gen Hosp, Dept Oncol, Harbin, Peoples R China

[26] China Med Univ, Hosp 1, Dept Med Oncol, Shenyang, Peoples R China

[27] IQVIA, Oncol Ctr Excellence, Therapeut Sci & Strategy Unit, Milan, Italy

[28] Kanagawa Canc Ctr, Dept Thorac Surg, Yokohama, Japan

[29] Univ Torino, Dept Surg Sci, Turin, Italy

[30] Azienda Osped Univ Citta Salute & Sci Torino, Dept Thorac Surg, Turin, Italy

[31] Univ Calif San Diego, Dept Med, La Jolla, CA USA

来源：

TRANSLATIONAL LUNG CANCER RESEARCH | 2023年 / 12卷 / 11期

关键词：

Osimertinib; comparator epidermal growth factor receptor tyrosine kinase inhibitor (comparator EGFR-TKI); propensity score matching (PSM); real-world study; OPEN-LABEL; FAMILY-HISTORY; SURVIVAL-DATA; PHASE-III; MUTATIONS; GEFITINIB; ADENOCARCINOMA; CHEMOTHERAPY; RESISTANCE; ERLOTINIB;

D O I：

10.21037/tlcr-23-577

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: In the phase 3 FLAURA trial, osimertinib was compared with first-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) as a first-line treatment for EGFR-mutant survival (OS), and a similar safety profile. However, more studies demonstrating the effectiveness and safety of osimertinib as a first-line strategy are needed in real-world populations. Methods: We enrolled 1,556 patients with EGFR-mutated stage IIIc-IV NSCLC from the CAPTRA-Lung database. All patients received either osimertinib (n=202) or a first-generation EGFR-TKI (n=1,354) as their initial treatment. To adjust for differences in baseline characteristics between two groups, 1:2 propensity mutations, and central nervous system (CNS) metastases. The standardized mean differences (SMD) before and after PSM were calculated to examine the balance of covariate distributions between two groups. Results: After PSM, 202 patients receiving osimertinib and 404 patients receiving first-generation 19.4 months [95% confidence interval (CI): 14.3-24.4] in the osimertinib arm and 10.9 months (95% CI: profile to that of comparator EGFR-TKIs when used as a first-line strategy in NSCLC patients.

引用

页码：2229 / +

页数：18

共 50 条

[31] First- versus Third-Generation EGFR Tyrosine Kinase Inhibitors in EGFR-Mutated Non-Small Cell Lung Cancer Patients with Brain Metastases
Tatineni, Vineeth
O'Shea, Patrick J.
Ozair, Ahmad
Khosla, Atulya A.
Saxena, Shreya
Rauf, Yasmeen
Jia, Xuefei
Murphy, Erin S.
Chao, Samuel T.
Suh, John H.
Peereboom, David M.
Ahluwalia, Manmeet S.
CANCERS, 2023, 15 (08)
[32] Real-world clinical outcomes of first-generation and second-generation epidermal growth factor receptor tyrosine kinase inhibitors in a large cohort of European non-small-cell lung cancer patients
Pluzanski, Adam
Krzakowski, Maciej
Kowalski, Dariusz
Dziadziuszko, Rafal
ESMO OPEN, 2020, 5 (06)
[33] Single-Center Real-World Study of First Line Afatinib Treatment in Advanced EGFR-mutated Non-small Cell Lung Cancer in Vietnam
Pham, C. T. M.
Hoang, T. T. A.
Truong, P. T.
Bui, P. T. T.
Nguyen, T. T.
Vo, T. N.
Tran, D. T.
Nguyen, D. T.
Tran, T. X.
Le, H. H.
Dong, H. Q.
Nguyen, K. T.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S662 - S663
[34] Efficacy and prognostic factors of first-line afatinib treatment for the EGFR-mutated non-small cell lung cancer in the real world
Chiu, Tzu Hsuan
Huang, Chi-Hsien
Kuo, Chih-Hsi Scott
EUROPEAN RESPIRATORY JOURNAL, 2020, 56
[35] PHARMACOECONOMIC ASPECTS OF DIFFERENT INHIBITORS OF TYROSINE KINASE IN FIRST-LINE THERAPY OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER WITH A MUTATION IN EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) GENE
Ryazhenov, V. V.
Gorokhova, S. G.
Gorokhov, V
VALUE IN HEALTH, 2016, 19 (07) : A720 - A720
[36] Real-world health utility scores and toxicities to tyrosine kinase inhibitors in epidermal growth factor receptor mutated advanced non-small cell lung cancer
Jiang, Shirley Xue
Walton, Ryan N.
Hueniken, Katrina
Baek, Justine
McCartney, Alexandra
Labbe, Catherine
Smith, Elliot
Chan, Sze Wah Samuel
Chen, RuiQi
Brown, Catherine
Patel, Devalben
Liang, Mindy
Eng, Lawson
Sacher, Adrian
Bradbury, Penelope
Leighl, Natasha B.
Shepherd, Frances A.
Xu, Wei
Liu, Geoffrey
Hurry, Manjusha
O'Kane, Grainne M.
CANCER MEDICINE, 2019, 8 (18): : 7542 - 7555
[37] A multicentre, real-world observational study of efficacy and safety of first-line osimertinib treatment in patients with epidermal growth factor receptor (EGFR) activating mutation-positive advanced non-small cell lung cancer (Reiwa study)
Fukui, T.
Naoki, K.
Yoh, K.
Usui, K.
Hosomi, Y.
Kishi, K.
Naka, G.
Watanabe, K.
Uemura, K.
Kunitoh, H.
ANNALS OF ONCOLOGY, 2022, 33 : S1583 - S1584
[38] Effect of early dose reduction of osimertinib on efficacy in the first-line treatment for EGFR-mutated non-small cell lung cancer
Hori, Tomoki
Yamamoto, Kazuhiro
Ito, Takefumi
Ikushima, Shigeki
Omura, Tomohiro
Yano, Ikuko
INVESTIGATIONAL NEW DRUGS, 2024, 42 (03) : 281 - 288
[39] Osimertinib in untreated epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer
Gregorc, Vanesa
Lazzari, Chiara
Karachaliou, Niki
Rosell, Rafael
Santarpia, Mariacarmela
TRANSLATIONAL LUNG CANCER RESEARCH, 2018, 7 : S165 - S170
[40] Histomolecular Resistance Mechanisms to First-Line Osimertinib in EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Multicentric Retrospective French Study
Assya Akli
Nicolas Girard
Vincent Fallet
Gaelle Rousseau-Bussac
Valérie Gounant
Sylvie Friard
Jean Trédaniel
Cécile Dujon
Marie Wislez
Boris Duchemann
Etienne Giroux-Leprieur
Targeted Oncology, 2022, 17 : 675 - 682

← 1 2 3 4 5 →